Isabelle Bernard‐Pierrot

2.9k citations

39 papers · 1.4k indexed · h-index 22

Molecular Biology top 10%
Surgery top 10%
Cancer Research top 10%
Oncology top 10%
Immunology top 10%

Co-authors: François Radvanyi Yves Allory Elodie Chapeaublanc Luca Grieco Aurélien de Reyniès José Courty Jean Paul Thiery Nicolas Stransky
Topics: Bladder and Urothelial Cancer Treatments (13 papers)Proteoglycans and glycosaminoglycans research (10 papers)Epigenetics and DNA Methylation (8 papers)
Cited by: Cancer Research Immunology and Allergy Molecular Biology
Journals: Journal of Biological Chemistry Nature Genetics Bioinformatics
Partner nations: France United Kingdom United States

In The Last Decade

Isabelle Bernard‐Pierrot

39 papers receiving 1.4k citations

Peers

Countries citing papers authored by Isabelle Bernard‐Pierrot

Since Specialization

Citations

This map shows the geographic impact of Isabelle Bernard‐Pierrot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Bernard‐Pierrot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Bernard‐Pierrot more than expected).

Fields of papers citing papers by Isabelle Bernard‐Pierrot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Bernard‐Pierrot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Bernard‐Pierrot. The network helps show where Isabelle Bernard‐Pierrot may publish in the future.

Co-authorship network of co-authors of Isabelle Bernard‐Pierrot

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Bernard‐Pierrot. A scholar is included among the top collaborators of Isabelle Bernard‐Pierrot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Bernard‐Pierrot. Isabelle Bernard‐Pierrot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition 2022 ·International Journal of Biological Sciences ·Sara Monteiro‐Reis,Vera Miranda‐Gonçalves,(unknown),(unknown),João Lobo,Diana Montezuma,Paula C. Dias,Hélène Neyret‐Kahn,Isabelle Bernard‐Pierrot,Rui Henrique,Cármen Jerónimo	14
2	Triple extraction method enables high quality mass spectrometry‐based proteomics and phospho‐proteomics for eventual multi‐omics integration studies 2021 ·PROTEOMICS ·Virginia Sánchez‐Quiles,Mingjun Shi,Florent Dingli,Clémentine Krucker,Damarys Loew,Isabelle Bernard‐Pierrot,François Radvanyi	2
3	Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy 2021 ·European Journal of Cancer ·Clarice S. Groeneveld,Jacqueline Fontugne,Luc Cabel,Isabelle Bernard‐Pierrot,François Radvanyi,Yves Allory,Aurélien de Reyniès	104
4	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer 2020 ·Genome Medicine ·Mingjun Shi,Xiangyu Meng,Jacqueline Fontugne,Chun-Long Chen,François Radvanyi,Isabelle Bernard‐Pierrot	30
5	An FGFR 3/ MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers 2018 ·EMBO Molecular Medicine ·(unknown),Florent Dufour,Hélène Neyret‐Kahn,(unknown),C Béraud,Mingjun Shi,Imène Hamaidi,Virginia Sánchez‐Quiles,Clémentine Krucker,(unknown),Elodie Chapeaublanc,Rémy Nicolle,Hervé Lang,Célio Pouponnot,Thierry Massfelder,François Radvanyi,Isabelle Bernard‐Pierrot	50
6	Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors 2018 ·Bioorganic & Medicinal Chemistry ·(unknown),Jessy Aziz,Florent Dufour,Valentina Abet,Véronique Stoven,François Radvanyi,Florent Poyer,Ting‐Di Wu,Jean‐Luc Guerquin‐Kern,Isabelle Bernard‐Pierrot,(unknown),Sandrine Piguel	10
7	IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer 2017 ·BMC Cancer ·Y. Neuzillet,Elodie Chapeaublanc,Clémentine Krucker,Leanne de Koning,Thierry Lebrét,François Radvanyi,Isabelle Bernard‐Pierrot	19
8	Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision 2013 ·PLoS Computational Biology ·Luca Grieco,Laurence Calzone,Isabelle Bernard‐Pierrot,François Radvanyi,Brigitte Kahn‐Perlès,Denis Thieffry	109
9	New Blocking Antibodies Impede Adhesion, Migration and Survival of Ovarian Cancer Cells, Highlighting MFGE8 as a Potential Therapeutic Target of Human Ovarian Carcinoma 2013 ·PLoS ONE ·(unknown),(unknown),Nicolás André,Sofie Notebaert,(unknown),(unknown),Cláudia Zuany‐Amorim,(unknown),Isabelle Bernard‐Pierrot,Xavier Sastre‐Garau,Clotilde Théry	38
10	Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation 2012 ·European Journal of Medicinal Chemistry ·(unknown),(unknown),(unknown),Nicolas Saettel,François Radvanyi,Sandrine Piguel,Isabelle Bernard‐Pierrot,Véronique Stoven,Michel Legraverend	29
11	The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells 2011 ·BMC Cancer ·Yamina Hamma‐Kourbali,(unknown),Isabelle Bernard‐Pierrot,(unknown),Dominique Martel-Renoir,(unknown),José Courty,Jean Delbé	14
12	A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression 2010 ·JNCI Journal of the National Cancer Institute ·Céline Vallot,Nicolas Stransky,Isabelle Bernard‐Pierrot,Aurélie Hérault,Jessica Zucman‐Rossi,Elodie Chapeaublanc,Dimitri Vordos,Agnès Laplanche,Simone Benhamou,Thierry Lebrét,Jennifer Southgate,Yves Allory,François Radvanyi	59
13	Milk fat globule—epidermal growth factor—factor VIII (MFGE8)/lactadherin promotes bladder tumor development 2010 ·Oncogene ·Gaël Sugano,Isabelle Bernard‐Pierrot,Marick Laé,Christophe Battail,Yves Allory,(unknown),Sophie Krumeich,(unknown),Patrick Maillé,M Donnadieu,C.C. Abbou,Simone Benhamou,(unknown),Xavier Sastre‐Garau,Sebastián Amigorena,François Radvanyi,Clotilde Théry	45
14	Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer 2008 ·Cancer Research ·Isabelle Bernard‐Pierrot,Nadège Gruel,Nicolas Stransky,Anne Vincent‐Salomon,Fabien Reyal,Virginie Raynal,Céline Vallot,Gaëlle Pierron,François Radvanyi,Olivier Delattre	73
15	Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b 2005 ·Carcinogenesis ·Isabelle Bernard‐Pierrot,(unknown),Claire Dunois-Lardé,Aurélie Caillault,Sixtina Gil Diez de Medina,David Cappellen,(unknown),Jean Paul Thiery,Dominique Chopin,(unknown),François Radvanyi	109
16	Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis 2004 ·Oncogene ·Mélanie Héroult,Isabelle Bernard‐Pierrot,Jean Delbé,Yamina Hamma‐Kourbali,Panagiotis Katsoris,Denis Barritault,Εvangelia Papadimitriou,Jean Plouët,José Courty	64
17	Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor 2004 ·Oncogene ·Isabelle Bernard‐Pierrot,(unknown),Andrew Cassidy,Alexander Graham,Paul Elvin,Aurélie Caillault,Séverine Lair,Philippe Broët,Jean Paul Thiery,François Radvanyi	35
18	Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine, in advanced solid tumor patients 2004 ·Cancer Detection and Prevention ·P Soulié,Mélanie Héroult,Isabelle Bernard‐Pierrot,Daniéle Caruelle,J Oglobine,Denis Barritault,José Courty	15
19	Heparin affin regulatory peptide in milk: its involvement in mammary gland homeostasis 2003 ·Biochemical and Biophysical Research Communications ·Isabelle Bernard‐Pierrot,Jean Delbé,Mélanie Héroult,Christophe Rosty,P Soulié,Denis Barritault,Pierre‐Emmanuel Milhiet,José Courty	2
20	Dominant Negative Effectors of Heparin Affin Regulatory Peptide (HARP) Angiogenic and Transforming Activities 2002 ·Journal of Biological Chemistry ·Isabelle Bernard‐Pierrot,Jean Delbé,(unknown),Marc Vigny,Marie‐Emmanuelle Kerros,Daniéle Caruelle,D. Raulais,Denis Barritault,José Courty,Pierre Emmanuel Milhiet	25

About Isabelle Bernard‐Pierrot

Isabelle Bernard‐Pierrot is a scholar working on Immunology and Allergy, Cell Biology and Immunology, having authored 39 papers that have together received 1.4k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (13 papers), Proteoglycans and glycosaminoglycans research (10 papers) and Epigenetics and DNA Methylation (8 papers). The work is most often cited by research in Cancer Research (291 citations), Immunology and Allergy (96 citations) and Molecular Biology (947 citations). Isabelle Bernard‐Pierrot has collaborated with scholars based in France, United Kingdom and United States. Frequent co-authors include François Radvanyi, Yves Allory, Elodie Chapeaublanc, Luca Grieco, Aurélien de Reyniès, José Courty, Jean Paul Thiery, Nicolas Stransky, Denis Barritault and Fabien Reyal. Their work appears in journals such as Journal of Biological Chemistry, Nature Genetics and Bioinformatics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact